| Version |
Status |
Last reviewed |
Endorsement date |
Implementation date |
1.2 |
Include the Victorian Infectious Diseases Reference Laboratory (VIDRL) as an additional laboratory where laboratory definitive evidence can be confirmed. Include footnote that the first case in Australia in any given outbreak will also be confirmed by CDC or NIV. |
CDWG - 31 October 2014 |
CDNA - 5 November 2014 |
6 November 2014 |
1.1 |
Laboratory definitive evidence
Added “or the Special Pathogens Laboratory, National Institute of Virology (NIV), Johannesburg”.
Removed “viral haemorrhagic fever” virus.
Added “specific” virus.
Added “or” antigen detection assay.
Removed “or electron microscopy” |
CDWG - 12 June 2013 |
CDNA - August 2014 |
1 January 2014 |
1.0 |
Initial CDNA case definition (2004). |
|
|
|
Reporting
Both confirmed cases and probable cases should be notified.
Confirmed case
A confirmed case requires laboratory definitive evidence only.
Laboratory definitive evidence
Laboratory definitive evidence requires confirmation by the Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne,* or the Special Pathogens Laboratory, CDC, Atlanta, or the Special Pathogens Laboratory, National Institute of Virology (NIV), Johannesburg
Isolation of a specific virus
OR
Detection of specific virus by nucleic acid testing or antigen detection assay
OR
IgG seroconversion or a significant increase in antibody level or a fourfold or greater rise in titre to specific virus.
Probable case
A probable case requires laboratory suggestive evidence AND clinical evidence AND epidemiological evidence.
Laboratory suggestive evidence
Isolation of virus pending confirmation by VIDRL, Melbourne, or CDC, Atlanta or NIV, Johannesburg
OR
Detection of specific virus by nucleic acid testing, pending confirmation by VIDRL, Melbourne, or CDC, Atlanta or NIV, Johannesburg
OR
IgG seroconversion or a significant increase in antibody level or a fourfold or greater rise in titre to specific virus pending confirmation by VIDRL, Melbourne, or CDC, Atlanta or NIV, Johannesburg
OR
Detection of IgM to a specific virus.
Clinical evidence
A compatible clinical illness as determined by an infectious disease physician. Common presenting complaints are fever myalgia, and prostration, with headache, pharyngitis, conjunctival injection, flushing, gastrointestinal symptoms. This may be complicated by spontaneous bleeding, petechiae, hypotension and perhaps shock, oedema and neurologic involvement.
Epidemiological evidence
History of travel to an endemic/epidemic area within 9 days (Marburg), 13 days (Crimean Congo) or 21 days (Lassa, Ebola) of illness onset. Filoviruses are endemic in Sub-Saharan Africa, Lassa in Western Africa, Crimean Congo in Africa and the Middle East to West China;
OR
Contact with a confirmed case,
OR
Exposure to viral haemorrhagic fever (VHF)-infected blood or tissues.
* The first case in any outbreak in Australia will also be confirmed by CDC, Atlanta or NIV, Johannesburg.
